Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 19/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 19/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082157 | 1.00 | ADRA1A (0.67) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7082162 | 1.00 | ADRA1A (0.67) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7967870 | 0.99 | ADRA1A (0.66) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7968446 | 0.99 | ADRA1A (0.66) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7967874 | 0.99 | ADRA1A (0.66) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7079598 | 0.91 | ADRA1D (0.54) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7081806 | 0.90 | ADRA1D (0.54) | ADRA1AADRA1DADRA1B | |
| SCHEMBL8150750 | 0.89 | ADRA1D (0.61) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL8150758 | 0.89 | ADRA1D (0.60) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7078214 | 0.88 | ADRA1A (0.83) | ADRA1AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | claimed |
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |